Nicotine as a potential neuroprotective agent for Parkinson’s disease
Identifieur interne : 003696 ( Ncbi/Checkpoint ); précédent : 003695; suivant : 003697Nicotine as a potential neuroprotective agent for Parkinson’s disease
Auteurs : Maryka Quik ; Xiomara A. Perez ; Tanuja BordiaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2012.
English descriptors
- KwdEn :
- Animals, Corpus Striatum (pathology), Disease Models, Animal, Humans, Neuroprotective Agents, Nicotine (therapeutic use), Nicotinic Agonists (therapeutic use), Parkinson Disease (prevention & control), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (prevention & control), Receptors, Nicotinic (drug effects), Signal Transduction (drug effects), Smoking (epidemiology), Substantia Nigra (pathology).
- MESH :
- chemical , drug effects : Receptors, Nicotinic.
- chemical , therapeutic use : Nicotine, Nicotinic Agonists.
- chemical : Neuroprotective Agents.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Signal Transduction.
- epidemiology : Smoking.
- pathology : Corpus Striatum, Substantia Nigra.
- prevention & control : Parkinson Disease, Parkinson Disease, Secondary.
- Animals, Disease Models, Animal, Humans.
Abstract
Converging research efforts suggest that nicotine and other drugs that act at nicotinic acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson’s disease. This idea initially stemmed from the results of epidemiological studies which demonstrate that smoking is associated with a decreased incidence of Parkinson’s disease. The subsequent finding that nicotine administration protected against nigrostriatal damage in parkinsonian animal models led to the idea that nicotine in tobacco products may contribute to this apparent protective action. Nicotine most likely exerts its effects by interacting at nAChRs. Accumulating research indicates that multiple subtypes, including α4β2, α6β2 and/or α7 containing nAChRs, may be involved. Stimulation of nAChRs initially activates various intracellular transduction pathways primarily via alterations in calcium signaling. Consequent adaptations in immune responsiveness and trophic factors may ultimately mediate nicotine’s ability to reduce/halt the neuronal damage that arises in Parkinson’s disease. In addition to a potential neuroprotective action, nicotine also has anti-depressant properties and improves attention/cognition. Altogether, these findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson’s disease.
Url:
DOI: 10.1002/mds.25028
PubMed: 22693036
PubMed Central: 3685410
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000269
- to stream Pmc, to step Curation: 000269
- to stream Pmc, to step Checkpoint: 000174
- to stream PubMed, to step Corpus: 000D50
- to stream PubMed, to step Curation: 000D50
- to stream PubMed, to step Checkpoint: 000D19
- to stream Ncbi, to step Merge: 003696
- to stream Ncbi, to step Curation: 003696
Links to Exploration step
PMC:3685410Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nicotine as a potential neuroprotective agent for Parkinson’s disease</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
</author>
<author><name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A." last="Perez">Xiomara A. Perez</name>
</author>
<author><name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22693036</idno>
<idno type="pmc">3685410</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685410</idno>
<idno type="RBID">PMC:3685410</idno>
<idno type="doi">10.1002/mds.25028</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">000269</idno>
<idno type="wicri:Area/Pmc/Curation">000269</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000174</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000D50</idno>
<idno type="wicri:Area/PubMed/Curation">000D50</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D19</idno>
<idno type="wicri:Area/Ncbi/Merge">003696</idno>
<idno type="wicri:Area/Ncbi/Curation">003696</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003696</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nicotine as a potential neuroprotective agent for Parkinson’s disease</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
</author>
<author><name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A." last="Perez">Xiomara A. Perez</name>
</author>
<author><name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Corpus Striatum (pathology)</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Neuroprotective Agents</term>
<term>Nicotine (therapeutic use)</term>
<term>Nicotinic Agonists (therapeutic use)</term>
<term>Parkinson Disease (prevention & control)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (prevention & control)</term>
<term>Receptors, Nicotinic (drug effects)</term>
<term>Signal Transduction (drug effects)</term>
<term>Smoking (epidemiology)</term>
<term>Substantia Nigra (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Nicotinic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nicotine</term>
<term>Nicotinic Agonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Smoking</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Converging research efforts suggest that nicotine and other drugs that act at nicotinic acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson’s disease. This idea initially stemmed from the results of epidemiological studies which demonstrate that smoking is associated with a decreased incidence of Parkinson’s disease. The subsequent finding that nicotine administration protected against nigrostriatal damage in parkinsonian animal models led to the idea that nicotine in tobacco products may contribute to this apparent protective action. Nicotine most likely exerts its effects by interacting at nAChRs. Accumulating research indicates that multiple subtypes, including α4β2, α6β2 and/or α7 containing nAChRs, may be involved. Stimulation of nAChRs initially activates various intracellular transduction pathways primarily via alterations in calcium signaling. Consequent adaptations in immune responsiveness and trophic factors may ultimately mediate nicotine’s ability to reduce/halt the neuronal damage that arises in Parkinson’s disease. In addition to a potential neuroprotective action, nicotine also has anti-depressant properties and improves attention/cognition. Altogether, these findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson’s disease.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name>
<name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A." last="Perez">Xiomara A. Perez</name>
<name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003696 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 003696 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= PMC:3685410 |texte= Nicotine as a potential neuroprotective agent for Parkinson’s disease }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:22693036" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |